Effectiveness and safety of COVID-19 vaccines in patients with oncological diseases: State-of-the-art.

Core Tip: The coronavirus disease 2019 (COVID-19) pandemic has greatly impacted the lives of cancer patients. Their medical care has been challenging, given the competing risks of death from cancer and serious complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Cancer patients are at high risk of severe complications and death from COVID-19. Protective SARS-CoV-2 antibodies and cellular immune response are induced after infection or/and COVID-19 vaccination. Vaccines decrease the risk of hospitalization and death from COVID-19. Therefore, vaccination of specific vulnerable groups, such as oncological patients, and all people in general, will slow the virus spread and save lives.

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has considerably impacted the lives of cancer patients. Their medical care has been challenging because of the competing risks of death from cancer or serious complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the likely higher lethality in immunocompromised hosts[ 1 , 2 ]. Furthermore, patients diagnosed with malignancies are at higher risk of developing severe COVID-19[ 3 ] and fatal outcomes due to the disease. Studies have demonstrated variable mortality rates among subjects with hematological cancers and solid tumors, with some reporting fatality cases of as much as 40% of the infected subjects[ 4 ]. Despite this considerably higher mortality than the one observed in the general population, trends towards improved survival during the evolution of the pandemic have already been demonstrated in Europe, and much of this could be a direct result of the rigorous COVID-19 vaccination in this region[ 5 ].

Since the beginning of the pandemic, hundreds of different therapeutic options have been studied, including those well-known in the treatment of other diseases, such as reoriented drugs. Amongst them are remdesivir (initially developed for hepatitis C treatment, tocilizumab-rheumatoid arthritis, hydroxychloroquine-malaria, lupus, etc ), corticosteroids, plasma from donors who have recovered from COVID-19, monoclonal antibodies (casirivimab + imdevimab, bamlanivimab, sotrovimab, cilgavimab + tixagevimab, etc ), Janus kinase inhibitors (baricitinib), and even mesenchymal stem cells[ 6 , 7 ]. Targeting both the virus itself and the host’s immune response with variable effectiveness during the different stages of the disease. However, prevention in the form of COVID vaccines remains the most desirable option for the general population both in long-term health-related and financial terms. Cancer patients are no exception in this regard. But exactly how effective are vaccines in cancer patients compared to the general population? This is the question we will try to answer.

In this review, we elucidated to what extent patients with cancer are at increased risk of developing severe COVID-19 and what is their overall case fatality rate. We also present the current concept and evidence on the effectiveness and safety of COVID-19 vaccines, including boosters, in oncology patients.

SEARCH STRATEGY

We performed a modified form of a biomedical narrative review according to recent recommendations for writing[ 8 ]. First, we thoroughly searched the scientific bibliographic databases Medline (PubMed) and Scopus. We used relevant free-text and Medical Subject Headings terms, as follows: (“COVID-19” OR “SARS-CoV-2”) AND (“cancer patients” OR “oncological patients”) AND (“COVID-19 vaccine” OR “mRNA vaccine”). We confined the search from January 1, 2020 to June 20, 2023. Then we identified additional papers using the search engine Google Scholar. Information from advisory committee meetings was also added.

COVID-19 AND PATIENTS WITH ONCOLOGICAL DISEASES

Patients with oncologic diseases are affected by SARS-CoV-2 in many different ways. Similar to many other infections, COVID-19 poses an additional risk of a fatal outcome for cancer patients. However, it is challenging to say to what extent patients with malignancies are threatened by complications of severe infections. As oncological diseases and treatment protocols are extremely diverse, it can be expected that the course of SARS-CoV2 infection would also be quite different[ 9 - 11 ].

The stage of disease, type of malignancy, and the sort and phase of the applied treatment modalities (surgery, chemotherapy, radiation therapy, and immunotherapy) introduce even more variables and more superimposing confounding factors, making this group of patients even more heterogeneous and difficult for overall risk assessment. Cancer patients who have recently undergone surgery or chemotherapy (especially during the induction phase with high-dose intensive regimens) are at a dramatically increased risk of death from COVID[ 12 , 13 ]. Side effects of chemotherapy, such as secondary immunodeficiency due to severe leukopenia and specific tissue toxicity due to some chemo- and immunotherapeutics, can significantly alter the course of COVID-19 infection, from worsening the patient’s overall condition and increasing the risk of complications and death to masking or mimicking the radiological pulmonary signs ( e.g. , immune checkpoint related pneumonitis)[ 13 ]. Finally, another confounding factor is the various therapeutic regimens used to treat infection in hospitals and intensive care units worldwide. Cancer patients are treated as high risk by default, which carries a risk (polypharmacy, drug interactions, adverse drug effects, acute kidney or liver failure, etc )[ 14 ].

Below, we present data from several studies that attempt to measure and objectify this risk. The first large-scale meta-analysis by 2020 done by Zhang et al [ 11 ] of 15 studies involving a total of 3019 patients from Europe, the United Kingdom, the United States, Canada, and Asia detected 22.4% circulating free RNAs (CFRs) in cancer patients with COVID-19, compared to 5.9% in noncancer patients. As in other patients, risk factors influencing the course and mortality are: Being over 65 years old, male sex, and having comorbidities (especially hypertension and diabetes). No significant difference in mortality was found between different continents. The study found that mortality in patients with lung cancer and hematological malignancies was highest, although the incidence of complications did not differ[ 11 ].

A study by Yang et al [ 15 ] involving 1575 patients, of whom 52 with various cancers (lung, colorectal, breast, cervical, thyroid, etc ) showed that oncologic patients are at higher risk of presenting as severe/critical cases and are more likely to develop acute respiratory distress syndrome. Also, other life-threatening complications such as myocardial infarction and shock are significantly increased in frequency. Lower lymphocyte count, as well as higher concentrations of C-reactive protein, D-dimer, procalcitonin, interleukin 6 (IL-6), and lactate dehydrogenase, were reported to reach P < 0.05. Cancer patients are also more likely to have comorbidities, which, as it becomes clear in this study, contributes seriously to the overall higher CFR[ 15 ].

A meta-analysis of 122 papers and 9 studies, including a total of 805 patients by Afshar et al [ 16 ], demonstrated how heterogeneous the data on mortality in cancer patients are. They showed that cancer patients are more likely to be admitted to intensive care units, need invasive ventilation, and are more likely to die. The published CFR in the analyzed studies ranges from 5.5% to 60.0%, with a pooled CFR of 21%. However, the authors warn that these data should be interpreted cautiously due to the high heterogeneity and the small number of patients in most studies[ 16 ].

Large-scale survival analysis by Li et al [ 9 ] based on data from United Kingdom Biobank followed 4606 cancer patients (288 positives) and 4606 noncancer patients (275 positives) for 21 mo after the SARS-CoV2 test. The cumulative CFR of the positive cancer patients was six times higher than the negative ones. The hazard ratio was assessed for each specific malignancy in the study, and the results showed that hematological malignancies, melanoma, kidney, and uterine cancer had particularly high CFRs (up to 10 times higher than the noncancer controls). The authors emphasize the importance of timely vaccination in these groups of patients[ 9 ].

In contrast to the data above, a study by Brar et al [ 17 ] included 585 patients, 117 with active malignancies. It showed no statistically significant difference in morbidity or mortality in cancer patients vs the general population. Furthermore, the authors argued that the studies claiming the opposite did not consider confounding factors such as age, sex, and comorbidities. According to this study, cytotoxic treatment within 90 d of admission is not associated with worse outcomes[ 17 ].

A team from London published a study in onco-hematology patients, where 40% (14 of 35) of patients hospitalized with COVID-19 had succumbed to the infection[ 18 ]. In general, COVID-19 appears to have an increased risk of complications and mortality in a large proportion of cancer patients. In addition, besides the virus itself, the pandemic and the restrictive measures were associated with disrupted access to medical care, hindered timely diagnosis and treatment, the lack of follow-up of many patients and lower quality of life[ 19 ]. Studies have shown that since the beginning of the pandemic, the total number of newly diagnosed cancers has dropped substantially[ 20 ]. As many authors warned, this inevitably led to an increased frequency of advanced cancers at diagnosis. Delaying diagnosis and treatment resulted in lower chances of survival[ 21 ]. Yong et al [ 22 ] conducted a study in Canada using microsimulation models, which estimated that for colorectal cancers, suspending primary screening for only 6 mo will increase cancer incidence by about 2200 cases, of which about 960 will be lethal over time. Consequences that otherwise would be prevented by the screening program and early detection.

Furthermore, there are many other indirect ways the COVID-19 pandemic affects cancer patients’ quality of life and mortality[ 13 ]. At the same time, the standard of living, the structure and stability of the health care system, and even political factors in connection with dealing with the pandemic play roles that should not be underestimated[ 23 ]. Knowing risk factors for the severity and mortality of COVID-19, cancer patients have their unique risk factors. They may include active and progressing cancer, type of cancer, administration of cytotoxic chemotherapy, radiation therapy, impaired immune system due to leukocytopenia, low immunoglobulin levels, long-lasting immunosuppression, comorbidities, and others.

Malignancies reported as comorbidities in patients hospitalized with confirmed COVID-19 in different countries are: (1) Malignancies in 7.2% in a cohort study with 138 adults with confirmed COVID-19 pneumonia in Wuhan, China, in January 2020[ 24 ]; (2) malignancies in 8% at admission in a cohort study with 1591 patients with laboratory-confirmed COVID-19 in Lombardy, Italy between February 20 and March 18, 2020[ 25 ]; and (3) Malignancies reported in 5.6% at admission in a cohort study with 5700 patients with confirmed COVID-19 infection hospitalized in 12 New York City hospitals between March 1 and April 4, 2020[ 26 ].

In a cohort study of 928 adults with COVID-19 and current or past cancer diagnosis, solid tumors were found in 82%, including breast (21%), hematologic (22%), prostate (16%), gastrointestinal (12%), thoracic (10%), gynecologic (5%), and renal cell carcinoma (5%)[ 27 , 28 ]. The estimated overall mortality in the research was 13%: 20% for patients with multiple cancers, 18% for patients with hematological malignancies, and 12% for patients with solid tumors[ 27 ].

Zhang et al [ 11 ] showed the COVID-19 fatality rates in subgroup analysis: (1) By cancer type: 32.9% in patients with lung cancer; 34.2% in patients with hematologic cancer; 17.2% in patients with solid cancer; and (2) By cancer treatment: 25.6% in patients with chemotherapy, 27.6% in patients with surgery, 24.3% in patients with immunotherapy, 21.3% in patients with targeted therapy, and 20.5% in patients with radiation therapy[ 11 ].

Children with cancer and positive for COVID-19 are at higher risk of severe illness than children without cancer. The cohort study found that about 20% of pediatric cancer patients with COVID-19 experienced a severe infection, compared to 1%-6% of children in the general population[ 29 ]. Among patients with hematologic malignancy and laboratory-confirmed COVID-19, mortality was reported in 34% of adults and 4% of children[ 4 ].

We can summarize that the main challenges in cancer patients regarding COVID-19 are the often immunocompromised state ( e.g., due to leukocytopenia, low immunoglobulin levels, long-lasting immunosuppression), the treatment ( e.g., severe chemotherapy, radiation therapy), progression of cancer, comorbidities, and others.

IMMUNE RESPONSE IN CANCER PATIENTS

Cancer cells induce an immune suppressive microenvironment and use various mechanisms to “escape” the body’s immune response. As a systemic disease, cancer causes a wide range of functional and compositional changes in the immune system and can affect the body’s defenses against various pathogens[ 30 , 31 ].

Dendritic cells (DCs) are antigen-presenting cells with an essential role in originating and directing cellular and humoral immune responses, converging innate and adaptive immunity. DCs have been recognized as the most potent professional antigen-presenting cells[ 32 ].

Tumors use different strategies to alter DC maturation and function, such as: (1) The ability to influence the capacity of hematopoietic progenitor cells to differentiate into functional DCs[ 33 , 34 ]; (2) production of various immunosuppressive factors that block the maturation of CD34+ stem cells into DCs[ 35 ]; and (3) spontaneous apoptosis of DCs in peripheral blood of patients with breast cancer[ 36 ]. Quantitative and functional DC deficiencies have been widely observed in patients with several types of cancer including breast cancer[ 37 , 38 ], prostate cancer[ 38 ], non-small cell lung cancer[ 39 , 40 ], colon cancer[ 41 ], and melanoma[ 42 ] .

Data have revealed that tumors disrupt normal hematopoiesis, leading to extramedullary hematopoiesis and myeloid skewing. The three branches of terminally differentiated myeloid cells (macrophages, DCs, and granulocytes) are essential for normal innate and adaptive immune response functioning. The tumor microenvironment alters myeloid cells and can convert them into potent immunosuppressive cells[ 43 , 44 ]. Lymphopenia caused by disease or treatment is frequent in oncology patients and affects their prognosis[ 45 , 46 ].

T cells, one of the primary arms of the adaptive immune response, are also affected in oncology patients. Cancer cells express various membrane and soluble T-cell inhibitory signals. For example, programmed cell death protein-ligand 1 linking to programmed cell death protein 1 on T cells results in decreased activation, proliferation, survival, and cytotoxicity[ 47 ]. The last discovery led to the development of checkpoint inhibitors, a breakthrough in immuno-oncology, which led to the 2018 Nobel Prize for Physiology or Medicine. Indoleamine 2,3-dioxygenase, a soluble enzyme physiologically expressed in many tissues, is overproduced in some cancers leading to tryptophan depletion in the tumor microenvironment. T cells, being highly sensitive to tryptophan deprivation, suffer significant functional impairment, promoting tumor growth[ 48 ]. An increased rate of CD4+CD25+ regulatory T cells with potent immunosuppressive properties in the peripheral blood of individuals with cancer diseases has been reported[ 49 , 50 ].

Additionally, regulatory B cells (Bregs) are a newly designated subset of B cells that play a central role in regulating immune responses associated with inflammation, autoimmunity, and cancer. Increased Bregs express immunosuppressive properties in gastric cancer through the secretion of anti-inflammatory molecules, such as IL-10, and facilitating the conversion of T cells to regulatory T cells[ 44 , 51 , 52 ]. Additionally, tumor progression is associated with the dysfunction of natural killer cells due to the combined action of tissue-specific and systemic factors[ 53 ]. All of these immune alterations in cancer patients contribute to the differences in immune response after vaccination, including after COVID-19 vaccine administration. Before the COVID-19 pandemic, we had an experience with influenza vaccine administration in patients with oncological diseases. Infectious complications resulting from bacterial, fungal, and viral (often due to reactivation of latent disease, primarily in patients with hematological malignancies) diseases are a severe cause of morbidity and mortality in cancer patients[ 54 ]. Oncology patients receiving chemotherapy are at increased risk of influenza virus infection and serious post-influenza complications. Cancer patients are eligible for influenza vaccination, although their response may be suboptimal due to immunosuppression associated with cancer itself and/or its treatment[ 55 , 56 ]. Data have shown that cancer patients receiving chemotherapy can respond to influenza vaccination[ 57 ].

Breast cancer patients receiving influenza vaccination during FEC (5-fluorouracil, epirubicin, and cyclophosphamide)-containing treatment regimens have exhibited significantly lower responses to influenza virus vaccination than healthy controls. Vaccination early during the chemotherapy cycle (day 4) induces better responses than vaccination on day 16[ 58 ]. The summary of the available evidence reveals that immunization of individuals with malignancies is critical to their care and may protect them from significant morbidity and mortality associated with vaccine-preventable diseases[ 59 ].

COVID-19 VACCINES FOR PATIENTS WITH ONCOLOGICAL DISEASES-DATA ON OUTCOMES AND EFFECTIVENESS

Several available COVID-19 vaccines are now in use all over the world. Moderate or severely immunocompromised people should receive a vaccination to protect them from severe COVID-19 disease[ 60 , 61 ].

The efficacy of COVID-19 vaccines in cancer patients is a question of continuous research, with most studies using immunological parameters as surrogate endpoints for clinical outcomes. Clinical trials investigating immune response after COVID-19 vaccination often use seroconversion to SARS-CoV-2 spike (S) protein as an endpoint for vaccine efficacy. Other parameters such as anti-spike antibody titers, detection of neutralizing antibodies, and cellular immune response are usually explored as secondary endpoints[ 62 ]. Some authors, however, underscore the role of neutralizing antibodies as the immunological parameter, which probably best correlates with the level of protection after COVID-19 vaccination[ 63 - 65 ].

Both humoral and cellular immune responses to COVID-19 vaccines differ in patients with malignancies compared to noncancer patients; this is not only attributed to the immunosuppressive nature of the oncologic disease but also to the antitumor therapy itself and its direct impact on immune cells. While patients with solid tumors have seroconversion rates similar to the general population, the most significant concern regarding post-vaccination and post-infectious COVID-19 immunity lies with hematological malignancies, especially those where lymphocyte-depletion therapy is used. In support of this is the research of Monin et al [ 66 ], who presented interim results of a prospective observational study that explores the immunogenicity of one compared to receiving two doses of the COVID-19 vaccine in patients with cancer by assessing the humoral immune response between 151 patients (95 with solid tumors and 56 with hematological malignancies) and 54 healthy controls. Authors reported efficacy after the first dose in 94%, 38%, and 18% of control subjects, patients with solid tumors and hematological cancer, respectively. After the second dose, the response increased to 100% in controls, 95% in patients with solid cancers, and only 60% in the group with hematological malignancies[ 66 ].

When considering post-vaccination immunity in patients with cancer, we should consider that those with hematological malignancies are expected to show different levels of antibody response to COVID-19 vaccines compared to patients with solid tumors. One of the most substantial pieces of evidence in corroboration came from the CAPTURE trial[ 67 ]. This prospective clinical study assessed the humoral response after COVID-19 vaccination in more than 700 subjects with solid tumors or hematologic neoplasms, 585 of whom did not have previous SARS-CoV-2 infection. The trial demonstrated 85% and 54% seroconversion rates for anti-spike antibodies after the second dose in patients with solid tumors and hematological malignancies, respectively. However, the response observed among participants was not the same for all SARS-CoV-2 variants[ 68 ].

The authors announced substantial differences in neutralizing antibodies concerning viral genotypes from the CAPTURE trial: 83% of patients developed detectable levels of the original SARS-CoV-2 and only 54% of the delta variant. And while nearly two-thirds (62%) of patients with solid tumors elicit humoral response against delta variant, only 31% of those with hematologic malignancies did so[ 67 ]. The prospective cohort study of immune response to COVID-19 vaccination in cancer patients CAPTURE ( NCT03226886 ) also showed that among 585 patients, the antibody rates after two doses of BNT162b2 or AZD1222 vaccines given over 12 wk were assessed. The results showed that seroconversion was 85% and 59% after two doses in patients with solid and hematological malignancies, respectively. Neutralizing antibodies against SARS-CoV-2 VOCs were detected in a small proportion of patients, mainly with solid cancers. Vaccine-induced T-cell responses were found in 80% of patients regardless of the vaccine or type of cancer[ 67 ].

In an attempt to overcome this relatively low rate of seroconversion in patients with blood cancers, Greenberger et al [ 69 ] conducted a large prospective cohort trial on nearly 700 patients vaccinated with three doses of the COVID-19 vaccine. It was estimated that antibody response indeed increased with the 3 rd (booster) dose, so 43% of those without detectable antibodies after the 2 nd dose demonstrated humoral response after the booster. However, about 20% of all hematological patients still failed to achieve a response even with 3 doses of vaccine[ 69 ]. In contrast to the plethora of research on humoral immunity after COVID-19 vaccination in cancer patients, the cellular immune response in this setting is considerably less studied. In a review article by Rüthrich et al [ 70 ], the authors tried to summarize what is currently known about the issue in patients with solid tumors and hematological malignancies, comparing data from COVID-19 vaccines and other ”classical” vaccines. Although the assessment of T-cell immune response in the reviewed studies varied, most research used methods based on quantifying and characterizing pathogen-specific T cells and/or estimating T-cell function by cytokine measurement[ 70 ].

Observations on immune responses in patients with hematological malignancies revealed that although this population may lack adequate levels of neutralizing viral antibodies, especially after treatment with B cell-depleting agents such as anti-cluster of differentiation 20 monoclonal antibodies, COVID-19 vaccines are still able to produce protective cellular immunity. Solid evidence for the sufficient efficacy of T-cell response comes from a trial in patients with agammaglobulinemia who demonstrated improved COVID-19 infection outcomes after vaccination. However, cellular immunity could also be impaired in this specific patient population, and some of the significant factors for this are age, disease activity, immunosuppressive treatment, and low lymphocyte counts in circulation[ 70 ].

This discordance between humoral and cellular immune response could also be seen In patients with solid tumors. In this population, T-cell responses vary among different cancer subtypes and are determined mainly by the type of systemic antitumor treatment. Various studies have demonstrated wide ranges in terms of cellular immunity achieved after COVID-19 vaccination ranging from about 50% to nearly 90% of the vaccinated cases[ 71 , 72 ].

However, despite being generally higher than those observed in blood cancer patients, T-cell response in those with solid tumors remains significantly lower than in healthy controls. One of the most extensive trials reporting data on immune response in patients with solid tumors receiving systemic anticancer treatment is the VOICE study[ 73 ]. After recruiting nearly 800 subjects (240 without cancer), the authors assessed cellular immunity by measuring the SARS-CoV-2 spike-specific interferon gamma T-cell response after two vaccine doses. They reported cellular responses in 67%, 66%, and 53% of patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy, respectively. Another interesting trial finding was that more than 40% of patients who did not elicit a humoral immune response could develop a T-cell response, highlighting the vaccine’s ‘double-edge sword’ efficacy in this specific population. Similar to the model observed with the humoral response, whether the cellular response is affected by a booster dose is still an open question since there are conflicting data. Some studies have reported significant enhancement of the T-cell response after the 3 rd dose, whereas others refute such assertions[ 73 ].

To date, most trials reporting COVID-19 vaccine efficacy in cancer rely on immunological endpoints and not so much on clinical outcomes. However, a recent study on infection rate and outcomes in vaccinated patients with solid tumors and hematologic malignancies has raised concern that despite vaccination, these patients remain at risk of worse outcomes compared to the general population[ 74 ]. Among fully vaccinated cancer patients, who experienced breakthrough SARS-CoV-2 infection, the hospitalization rate, intensive care unit admission (or required mechanical vaccination), and death rate are 65%, 19%, and 13%, respectively. This is mainly attributed to patients’ comorbidities and the much worse COVID-19 prognosis in those with hematological malignancies.

In a prospective study conducted by Goshen-Lago et al [ 75 ], it was shown that patients with solid tumors demonstrated short-term efficacy and safety of the BNT162b2 vaccine. A follow-up study evaluated these outcomes at 6 mo after vaccination[ 76 ]. Participants were 154 patients with solid tumors and 135 controls (health workers). At 6 mo after vaccination, 122 patients were seropositive compared with 114 controls, and the serologic titers dramatically decreased almost equally in both cohorts. Efficacy and safety evidence of BNT162b2 vaccines shows that the serological profile in cancer patients after 6 mo resembles that of the general population[ 76 ].

A similar study was conducted by Barrière et al [ 77 ], who evaluated the immunogenicity of the BNT162b2 vaccine in patients with solid tumors. Serological analyses were performed during the first vaccination, during the booster dose (w3-w4), and 3-4 wk after the booster dose (w6-w8). The study reported the results for 122 of 194 evaluable patients with solid tumors who had at least two doses from January 2021 to March 2021. In the first analysis (w3-w4), 58 patients had neutralizing antibodies, although the median levels were significantly lower than in the control group. In the following analysis (w6-w8), the data showed the same anti-S seroconversion rate, demonstrating impaired immunogenicity of the BNT162b2 vaccine in cancer patients[ 77 ].

Shroff et al [ 78 ] also compared anti-S seroconversion to the BNT162b2 mRNA vaccine in patients with solid tumors on active cytotoxic anticancer therapy with healthy control participants. Neutralizing antibodies were found in 67% of cancer patients after the first immunization, and a follow-up analysis found a threefold increase in titers after the second or third doses. European Union Drug Regulating Authorities Clinical Trials (EudraCT) Number 2021-000291-11 was conducted in patients with solid cancers, multiple myeloma, and inflammatory bowel disease[ 79 ]. The study is a prospective, open-label, phase four trial to monitor vaccine-specific antibody and cellular responses after booster vaccination with mRNA-1273 or BNT162b2. The data show that booster vaccination against SARS-CoV-2 reverses the lack of response and early antibody weakening in immunocompromised patients.

Another study on the efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA vaccine in cancer patients without antibody response was conducted in 2022[ 80 ]. The assessment was done directly before vaccination and 4 wk after. Ad26.COV2.S booster vaccination resulted in a serological response in 31% of nonresponders after a double dose of BNT162b2. Clinical trials with the number NCT04368728 reported results from individuals with a history of past or active neoplasms and up to 6 mo of follow-up after dose 2 of a placebo-controlled, observer-blinded trial of the BNT162b2 vaccine[ 81 ]. In participants with past or active neoplasms, two doses of the BNT162b2 vaccine improved efficacy and safety profile as in the overall trial population. No vaccine-related deaths were reported.

One of the first evaluations of the effectiveness of vaccination against breakthrough SARS-CoV-2 infections in cancer patients at a population level was done by Lee et al [ 82 ]. Analysis was performed in the cancer cohort by vaccine type (BNT162b2, ChAdOx1 nCov-19, or mixed, and other), cancer type and subtype, stage, date of cancer diagnosis, and anticancer treatment or radiotherapy. Data show that vaccination with different COVID-19 vaccines is effective in people with cancer, providing varying levels of protection against SARS-CoV-2 infection. However, it is lower in cancer patients than in the general population[ 82 ].

A single-arm prospective clinical trial was conducted with 106 cancer patients by Thakkar et al [ 83 ]. They received two doses of mRNA followed by one dose of AD26.CoV2.S vaccine or a third dose of mRNA vaccine. The results showed that a third dose induced immunity in cancer patients. Seroconversion was also assessed in 57% of patients who did not respond to primary vaccination. A fourth dose boosted the immune response by two-thirds. Some patients have neutralizing activity against the omicron variant[ 83 ].

In conclusion, all of these studies confirm that people with cancer are at increased risk of severe COVID-19 disease, hospitalization, and death after SARS-CoV-2 infection compared to the general population. The above data show that cancer patients have impaired overall vaccine effectiveness to the approved COVID-19 vaccines. Seroconversion in them decreases faster than in the control population. Although vaccination provides different levels of protection, there should be a global prioritization of the programs to boost vaccination for cancer people, considering the impact of other treatments.

There are still a lack of data on vaccine efficacy in cancer patients concerning novel virus variants like omicron[ 68 ]. Table 1 presents the studies on the effectiveness and safety of COVID-19 vaccination with different approved COVID-19 vaccines in oncological patients with solid tumors[ 5 , 63 , 66 , 67 , 69 - 71 , 73 , 75 - 84 , 84 ].

COVID-19 VACCINES AND CHEMOTHERAPY INTERACTIONS

People with cancer often have an increased susceptibility to infections due to various factors, including cancer itself and/or, in some cases, the applied therapy, poor nutrition, and damaged physiological barriers. In addition, the incidence of neoplasia is highest in individuals aged 65 and over. When the immune system’s effectiveness is weakened, the elderly often have concomitant diseases for which they can also take medications[ 54 , 85 ].

Regarding cancer chemotherapy, conventional antitumor chemotherapeutic agents kill actively proliferating cells, including bone marrow cells, and myelosuppression is one of clinical oncology’s most common side effects[ 86 ]. Chemotherapy-induced neutropenia is a significant cause of hematological and dose-limiting toxicities of chemotherapy[ 87 ]. Some currently available anticancer drugs, such as methotrexate and cyclophosphamide, express immunosuppressive effects and impair peripheral T cells’ proliferative and/or effector functions. Methotrexate is an antimetabolite of the antifolate type developed in 1947 and is included in the World Health Organization’s List of Essential Medicines. Currently, it is widely used not only in clinical oncology (in the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, meningeal leukemia and lymphoma, osteosarcomas, non-Hodgkin’s lymphoma, breast and bladder cancers, etc .) but also as a first-line treatment in autoimmune, inflammatory diseases such as rheumatoid arthritis, psoriasis and Crone’s disease[ 88 - 90 ]. Methotrexate has been found to disturb antibody response after pneumococcal vaccination[ 91 , 92 ]; the drug reduces circulating T helper 17 (Th17) cells and impairs plasmablast and memory B-cell expansion following pneumococcal conjugate immunization in patients with rheumatoid arthritis[ 93 ].

Cyclophosphamide is an alkylating agent synthesized in 1958 and used for decades in clinical practice in the therapy regimens of neoplasms (malignant lymphomas, multiple myeloma, sarcoma, breast cancer, disseminated neuroblastomas, retinoblastoma, ovarian adenocarcinoma, etc ) and as an immunosuppressive agent for the treatment of autoimmune and immune-mediated diseases such as multiple sclerosis. Cyclophosphamide shows selectivity for T cells and is an immunosuppressant to prevent transplant rejection and graft- vs -host complications[ 94 ]. Cyclophosphamide has been associated with suppressing helper Th1 activity and enhancing Th2 responses[ 95 ]. This drug inhibits Th1/Th17 responses and increases the cells secreting anti-inflammatory cytokines such as IL-4, IL-10, and transforming growth factor beta[ 96 ]. A single administration of low-dose cyclophosphamide selectively suppresses regulatory T cells. The low-dose cyclophosphamide promotes antitumor immunity by selectively depleting regulatory T cells and enhancing effector T cell function. However, cyclophosphamide can also increase the number of myeloid-derived suppressor cells[ 97 , 98 ].

Treatment with tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib applied in the treatment of chronic myeloid leukemia is associated with loss of memory B-cell subsets and impaired humoral immune responses to 23-valent polysaccharide pneumococcal vaccine, likely due to the off-target kinase inhibitory activity of these drugs[ 99 ].

CONCLUSION

Data so far show that patients with cancer are at increased risk of severe COVID-19 and developing various complications mainly due to their immunocompromised state, type of treatment and comorbidities. Although cancer patients were excluded from vaccine trials, the investigations of post-vaccinal immune responses and the effectiveness of the vaccines showed that both humoral and cellular immune responses to COVID-19 vaccines differ in patients with malignancies compared to noncancer patients, and this is being attributed not only to the immunosuppressive nature of the oncologic disease but to the antitumor therapy itself and its direct impact on immune cells.

The evidence indicates that the efficacy of vaccinations could be impaired in cancer patients in line with a reduced rate of seroconversion and shorter duration compared to healthy controls. Despite these data, when focusing on the clinical outcomes instead of immunological endpoints regarding vaccine efficacy, COVID-19 vaccines demonstrated high effectiveness in preventing severe COVID-19 and infection-related death, and safety profile with comparable to healthy controls adverse effects in patients with solid tumors and hematological malignancies.

Despite the considerably higher mortality in the cancer patients group from COVID-19 than the general population, countries with high vaccination rates have demonstrated trends toward improved survival of cancer patients early and late in the pandemic. Nevertheless, vaccination of these patients and overall vaccination of the population has proven to significantly reduce the risk of complications and mortality of COVID-19 and should be promoted worldwide.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review started: June 28, 2023

First decision: July 6, 2023

Article in press: September 12, 2023

Specialty type: Oncology

Country/Territory of origin: Bulgaria

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Chen LJ, China; Emran TB, Bangladesh S-Editor: Chen YL L-Editor: Filipodia P-Editor: Chen YL

1 Yu J Ouyang W Chua MLK Xie C SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China JAMA Oncol 2020 6 1108 1110 32211820 10.1001/jamaoncol.2020.0980 PMC7097836

2 Lewis MA Between Scylla and Charybdis-Oncologic Decision Making in the Time of Covid-19 N Engl J Med 2020 382 2285 2287 32267650 10.1056/NEJMp2006588

3 ElGohary GM Hashmi S Styczynski J Kharfan-Dabaja MA Alblooshi RM de la Cámara R Mohmed S Alshaibani A Cesaro S Abd El-Aziz N Almaghrabi R Gergis U Majhail NS El-Gohary Y Chemaly RF Aljurf M El Fakih R The Risk and Prognosis of COVID-19 Infection in Cancer Patients: A Systematic Review and Meta-Analysis Hematol Oncol Stem Cell Ther 2022 15 45 53 32745466 10.1016/j.hemonc.2020.07.005 PMC7390725

4 Vijenthira A Gong IY Fox TA Booth S Cook G Fattizzo B Martín-Moro F Razanamahery J Riches JC Zwicker J Patell R Vekemans MC Scarfò L Chatzikonstantinou T Yildiz H Lattenist R Mantzaris I Wood WA Hicks LK Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients Blood 2020 136 2881 2892 33113551 10.1182/blood.2020008824 PMC7746126

5 OnCovid Study Group Pinato DJ Patel M Scotti L Colomba E Dolly S Loizidou A Chester J Mukherjee U Zambelli A Dalla Pria A Aguilar-Company J Bower M Salazar R Bertuzzi A Brunet J Lambertini M Tagliamento M Pous A Sita-Lumsden A Srikandarajah K Colomba J Pommeret F Seguí E Generali D Grisanti S Pedrazzoli P Rizzo G Libertini M Moss C Evans JS Russell B Harbeck N Vincenzi B Biello F Bertulli R Ottaviani D Liñan R Rossi S Carmona-García MC Tondini C Fox L Baggi A Fotia V Parisi A Porzio G Queirolo P Cruz CA Saoudi-Gonzalez N Felip E Roqué Lloveras A Newsom-Davis T Sharkey R Roldán E Reyes R Zoratto F Earnshaw I Ferrante D Marco-Hernández J Ruiz-Camps I Gaidano G Patriarca A Bruna R Sureda A Martinez-Vila C Sanchez de Torre A Berardi R Giusti R Mazzoni F Guida A Rimassa L Chiudinelli L Franchi M Krengli M Santoro A Prat A Tabernero J Van Hemelrijck M Diamantis N Gennari A Cortellini A Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry JAMA Oncol 2022 8 114 122 34817562 10.1001/jamaoncol.2021.6199 PMC8777559

6 Chen L Qu J Kalyani FS Zhang Q Fan L Fang Y Li Y Xiang C Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications Cell Mol Life Sci 2022 79 142 35187617 10.1007/s00018-021-04096-y PMC8858603

7 Yuan Y Jiao B Qu L Yang D Liu R The development of COVID-19 treatment Front Immunol 2023 14 1125246 36776881 10.3389/fimmu.2023.1125246 PMC9909293

8 Gasparyan AY Ayvazyan L Blackmore H Kitas GD Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors Rheumatol Int 2011 31 1409 1417 21800117 10.1007/s00296-011-1999-3

9 Li H Baldwin E Zhang X Kenost C Luo W Calhoun EA An L Bennett CL Lussier YA Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate controlling for age, sex and cancer type BMJ Health Care Inform 2021 28 10.1136/bmjhci-2021-100341 PMC8117441 33980502

10 He W Chen L Yuan G Fang Y Chen W Wu D Liang B Lu X Ma Y Li L Wang H Chen Z Li Q Gale RP COVID-19 in persons with haematological cancers Leukemia 2020 34 1637 1645 32332856 10.1038/s41375-020-0836-7 PMC7180672

11 Zhang H Han H He T Labbe KE Hernandez AV Chen H Velcheti V Stebbing J Wong KK Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis J Natl Cancer Inst 2021 113 371 380 33136163 10.1093/jnci/djaa168 PMC7665647

12 Aries JA Davies JK Auer RL Hallam SL Montoto S Smith M Sevillano B Foggo V Wrench B Zegocki K Agrawal S Le Dieu R Truelove E Erblich T Araf S Okosun J Oakervee H Cavenagh JD Gribben JG Riches JC Clinical outcome of coronavirus disease 2019 in haemato-oncology patients Br J Haematol 2020 190 e64 e67 32420609 10.1111/bjh.16852 PMC7276898

13 Tsamakis K Gavriatopoulou M Schizas D Stravodimou A Mougkou A Tsiptsios D Sioulas V Spartalis E Sioulas AD Tsamakis C Charalampakis N Mueller C Arya D Zarogoulidis P Spandidos DA Dimopoulos MA Papageorgiou C Rizos E Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients Oncol Lett 2020 20 441 447 32565968 10.3892/ol.2020.11599 PMC7285823

14 Iloanusi S Mgbere O Essien EJ Polypharmacy among COVID-19 patients: A systematic review J Am Pharm Assoc (2003) 2021 61 e14 e25 10.1016/j.japh.2021.05.006 PMC8149164 34120855

15 Yang F Shi S Zhu J Shi J Dai K Chen X Clinical characteristics and outcomes of cancer patients with COVID-19 J Med Virol 2020 92 2067 2073 32369209 10.1002/jmv.25972

16 Afshar ZM Dayani M Naderi M Ghanbarveisi F Shiri S Rajati F Fatality rate of COVID-19 in patients with malignancies: a sytematic review and meta-analysis J Infect 2020 81 e114 e116 32474042 10.1016/j.jinf.2020.05.062 PMC7255731

17 Brar G Pinheiro LC Shusterman M Swed B Reshetnyak E Soroka O Chen F Yamshon S Vaughn J Martin P Paul D Hidalgo M Shah MA COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study J Clin Oncol 2020 38 3914 3924 32986528 10.1200/JCO.20.01580 PMC7676890

18 Onder G Rezza G Brusaferro S Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy JAMA 2020 323 1775 1776 32203977 10.1001/jama.2020.4683

19 Guven DC Aktas BY Aksun MS Ucgul E Sahin TK Yildirim HC Guner G Kertmen N Dizdar O Kilickap S Aksoy S Yalcin S Turker A Uckun FM Arik Z COVID-19 pandemic: changes in cancer admissions BMJ Support Palliat Care 2020 10.1136/bmjspcare-2020-002468 32665259

20 Skovlund CW Friis S Christensen J Nilbert MC Mørch LS Drop in cancer diagnosis during the COVID-19 pandemic in Denmark: assessment of impact during 2020 Acta Oncol 2022 61 658 661 35020549 10.1080/0284186X.2021.2024879

21 Vázquez Rosas T Cazap E Delgado L Ismael J Bejarano S Castro C Castro H Müller B Gutiérrez-Delgado F Santini LA Vallejos Sologuren C Social Distancing and Economic Crisis During COVID-19 Pandemic Reduced Cancer Control in Latin America and Will Result in Increased Late-Stage Diagnoses and Expense JCO Glob Oncol 2021 7 694 703 33999696 10.1200/GO.21.00016 PMC8162975

22 Yong JH Mainprize JG Yaffe MJ Ruan Y Poirier AE Coldman A Nadeau C Iragorri N Hilsden RJ Brenner DR The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada J Med Screen 2021 28 100 107 33241760 10.1177/0969141320974711 PMC7691762

23 Salunke AA Nandy K Pathak SK Shah J Kamani M Kottakota V Thivari P Pandey A Patel K Rathod P Bhatt S Dave P Pandya S Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis Diabetes Metab Syndr 2020 14 1431 1437 32755847 10.1016/j.dsx.2020.07.037 PMC7833306

24 Wang D Hu B Hu C Zhu F Liu X Zhang J Wang B Xiang H Cheng Z Xiong Y Zhao Y Li Y Wang X Peng Z Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China JAMA 2020 323 1061 1069 32031570 10.1001/jama.2020.1585 PMC7042881

25 Grasselli G Zangrillo A Zanella A Antonelli M Cabrini L Castelli A Cereda D Coluccello A Foti G Fumagalli R Iotti G Latronico N Lorini L Merler S Natalini G Piatti A Ranieri MV Scandroglio AM Storti E Cecconi M Pesenti A COVID-19 Lombardy ICU Network Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy JAMA 2020 323 1574 1581 32250385 10.1001/jama.2020.5394 PMC7136855

26 Richardson S Hirsch JS Narasimhan M Crawford JM McGinn T Davidson KW the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area JAMA 2020 323 2052 2059 32320003 10.1001/jama.2020.6775 PMC7177629

27 Kuderer NM Choueiri TK Shah DP Shyr Y Rubinstein SM Rivera DR Shete S Hsu CY Desai A de Lima Lopes G Jr Grivas P Painter CA Peters S Thompson MA Bakouny Z Batist G Bekaii-Saab T Bilen MA Bouganim N Larroya MB Castellano D Del Prete SA Doroshow DB Egan PC Elkrief A Farmakiotis D Flora D Galsky MD Glover MJ Griffiths EA Gulati AP Gupta S Hafez N Halfdanarson TR Hawley JE Hsu E Kasi A Khaki AR Lemmon CA Lewis C Logan B Masters T McKay RR Mesa RA Morgans AK Mulcahy MF Panagiotou OA Peddi P Pennell NA Reynolds K Rosen LR Rosovsky R Salazar M Schmidt A Shah SA Shaya JA Steinharter J Stockerl-Goldstein KE Subbiah S Vinh DC Wehbe FH Weissmann LB Wu JT Wulff-Burchfield E Xie Z Yeh A Yu PP Zhou AY Zubiri L Mishra S Lyman GH Rini BI Warner JL COVID-19 and Cancer Consortium Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Lancet 2020 395 1907 1918 32473681 10.1016/S0140-6736(20)31187-9 PMC7255743

28 Jee J Foote MB Lumish M Stonestrom AJ Wills B Narendra V Avutu V Murciano-Goroff YR Chan JE Derkach A Philip J Belenkaya R Kerpelev M Maloy M Watson A Fong C Janjigian Y Diaz LA Jr Bolton KL Pessin MS Chemotherapy and COVID-19 Outcomes in Patients With Cancer J Clin Oncol 2020 38 3538 3546 32795225 10.1200/JCO.20.01307 PMC7571792

29 Mukkada S Bhakta N Chantada GL Chen Y Vedaraju Y Faughnan L Homsi MR Muniz-Talavera H Ranadive R Metzger M Friedrich P Agulnik A Jeha S Lam C Dalvi R Hessissen L Moreira DC Santana VM Sullivan M Bouffet E Caniza MA Devidas M Pritchard-Jones K Rodriguez-Galindo C Global Registry of COVID-19 in Childhood Cancer Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study Lancet Oncol 2021 22 1416 1426 34454651 10.1016/S1470-2045(21)00454-X PMC8389979

30 Vinay DS Ryan EP Pawelec G Talib WH Stagg J Elkord E Lichtor T Decker WK Whelan RL Kumara HMCS Signori E Honoki K Georgakilas AG Amin A Helferich WG Boosani CS Guha G Ciriolo MR Chen S Mohammed SI Azmi AS Keith WN Bilsland A Bhakta D Halicka D Fujii H Aquilano K Ashraf SS Nowsheen S Yang X Choi BK Kwon BS Immune evasion in cancer: Mechanistic basis and therapeutic strategies Semin Cancer Biol 2015 35 Suppl S185 S198 25818339 10.1016/j.semcancer.2015.03.004

31 Hiam-Galvez KJ Allen BM Spitzer MH Systemic immunity in cancer Nat Rev Cancer 2021 21 345 359 33837297 10.1038/s41568-021-00347-z PMC8034277

32 Nesmiyanov PP Dendritic Cells Encyclop of Infect and Immun 2022 1 110 117

33 Gabrilovich DI Chen HL Girgis KR Cunningham HT Meny GM Nadaf S Kavanaugh D Carbone DP Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nat Med 1996 2 1096 1103 8837607 10.1038/nm1096-1096

34 Menetrier-Caux C Montmain G Dieu MC Bain C Favrot MC Caux C Blay JY Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor Blood 1998 92 4778 4791 9845545

35 Kiertscher SM Luo J Dubinett SM Roth MD Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells J Immunol 2000 164 1269 1276 10640740 10.4049/jimmunol.164.3.1269

36 Pinzon-Charry A Maxwell T McGuckin MA Schmidt C Furnival C López JA Spontaneous apoptosis of blood dendritic cells in patients with breast cancer Breast Cancer Res 2006 8 R5 16417648 10.1186/bcr1361 PMC1413992

37 Della Bella S Gennaro M Vaccari M Ferraris C Nicola S Riva A Clerici M Greco M Villa ML Altered maturation of peripheral blood dendritic cells in patients with breast cancer Br J Cancer 2003 89 1463 1472 14562018 10.1038/sj.bjc.6601243 PMC2394334

38 Mastelic-Gavillet B Sarivalasis A Lozano LE Wyss T Inoges S de Vries IJM Dartiguenave F Jichlinski P Derrè L Coukos G Melero I Harari A Romero P Viganó S Kandalaft LE Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer Eur J Cancer 2020 135 173 182 32590296 10.1016/j.ejca.2020.04.036

39 Tabarkiewicz J Rybojad P Jablonka A Rolinski J CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer Oncol Rep 2008 19 237 243 18097601

40 Lu Y Xu W Gu Y Chang X Wei G Rong Z Qin L Chen X Zhou F Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c(+) Conventional Dendritic Cell Subsets Mediated by CD103 and CD205 Front Immunol 2019 10 2829 31921114 10.3389/fimmu.2019.02829 PMC6914740

41 Legitimo A Consolini R Failli A Orsini G Spisni R Dendritic cell defects in the colorectal cancer Hum Vaccin Immunother 2014 10 3224 3235 25483675 10.4161/hv.29857 PMC4514061

42 Failli A Legitimo A Orsini G Romanini A Consolini R Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma Cancer Lett 2013 337 184 192 23684927 10.1016/j.canlet.2013.05.013

43 Gabrilovich DI Ostrand-Rosenberg S Bronte V Coordinated regulation of myeloid cells by tumours Nat Rev Immunol 2012 12 253 268 22437938 10.1038/nri3175 PMC3587148

44 Wang WW Yuan XL Chen H Xie GH Ma YH Zheng YX Zhou YL Shen LS CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer Oncotarget 2015 6 33486 33499 26378021 10.18632/oncotarget.5588 PMC4741780

45 Ray-Coquard I Cropet C Van Glabbeke M Sebban C Le Cesne A Judson I Tredan O Verweij J Biron P Labidi I Guastalla JP Bachelot T Perol D Chabaud S Hogendoorn PC Cassier P Dufresne A Blay JY European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas Cancer Res 2009 69 5383 5391 19549917 10.1158/0008-5472.CAN-08-3845 PMC2775079

46 Wang JL Ma R Kong W Zhao R Wang YY Lymphopenia in Esophageal Cancer: What Have We Learned? Front Oncol 2021 11 625963 33791213 10.3389/fonc.2021.625963 PMC8006429

47 Han Y Liu D Li L PD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res 2020 10 727 742 32266087 PMC7136921

48 Ye Q Wang C Xian J Zhang M Cao Y Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer Hum Pathol 2018 75 81 90 29447919 10.1016/j.humpath.2018.02.004

49 Wolf AM Wolf D Steurer M Gastl G Gunsilius E Grubeck-Loebenstein B Increase of regulatory T cells in the peripheral blood of cancer patients Clin Cancer Res 2003 9 606 612 12576425

50 Liu L Wu G Yao JX Ding Q Huang SA CD4+CD25high regulatory cells in peripheral blood of cancer patients Neuro Endocrinol Lett 2008 29 240 245 18404145

51 Sarvaria A Madrigal JA Saudemont A B cell regulation in cancer and anti-tumor immunity Cell Mol Immunol 2017 14 662 674 28626234 10.1038/cmi.2017.35 PMC5549607

52 Murakami Y Saito H Shimizu S Kono Y Shishido Y Miyatani K Matsunaga T Fukumoto Y Ashida K Sakabe T Nakayama Y Fujiwara Y Increased regulatory B cells are involved in immune evasion in patients with gastric cancer Sci Rep 2019 9 13083 31511630 10.1038/s41598-019-49581-4 PMC6739478

53 Li JH O'Sullivan TE Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function Front Immunol 2021 12 816658 35082797 10.3389/fimmu.2021.816658 PMC8785903

54 Zembower TR Epidemiology of infections in cancer patients Cancer Treat Res 2014 161 43 89 24706221 10.1007/978-3-319-04220-6_2 PMC7120867

55 Bitterman R Eliakim-Raz N Vinograd I Zalmanovici Trestioreanu A Leibovici L Paul M Influenza vaccines in immunosuppressed adults with cancer Cochrane Database Syst Rev 2018 2 CD008983 29388675 10.1002/14651858.CD008983.pub3 PMC6491273

56 Brydak LB Guzy J Starzyk J Machała M Góźdź SS Humoral immune response after vaccination against influenza in patients with breast cancer Support Care Cancer 2001 9 65 68 11147146 10.1007/s005200000186

57 Pollyea DA Brown JM Horning SJ Utility of influenza vaccination for oncology patients J Clin Oncol 2010 28 2481 2490 20385981 10.1200/JCO.2009.26.6908

58 Oates HF Stoker LM Monaghan JC Stokes GS The beta-adrenoceptor controlling renin release Arch Int Pharmacodyn Ther 1978 234 205 213 213037

59 Arrowood JR Hayney MS Immunization recommendations for adults with cancer Ann Pharmacother 2002 36 1219 1229 12086557 10.1345/aph.1A277

60 Velikova T Georgiev T SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis Rheumatol Int 2021 41 509 518 33515320 10.1007/s00296-021-04792-9 PMC7846902

61 Sen P Ravichandran N Nune A Lilleker JB Agarwal V Kardes S Kim M Day J Milchert M Gheita T Salim B Velikova T Gracia-Ramos AE Parodis I Selva O'Callaghan A Nikiphorou E Chatterjee T Tan AL Cavagna L Saavedra MA Shinjo SK Ziade N Knitza J Kuwana M Distler O Chinoy H Aggarwal R Gupta L COVAD Study Group COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study Rheumatology (Oxford) 2022 62 65 76 35713499 10.1093/rheumatology/keac305 PMC9214139

62 Corti C Antonarelli G Scotté F Spano JP Barrière J Michot JM André F Curigliano G Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review Ann Oncol 2022 33 158 168 34718117 10.1016/j.annonc.2021.10.014 PMC8552625

63 Khoury DS Cromer D Reynaldi A Schlub TE Wheatley AK Juno JA Subbarao K Kent SJ Triccas JA Davenport MP Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Nat Med 2021 27 1205 1211 34002089 10.1038/s41591-021-01377-8

64 Earle KA Ambrosino DM Fiore-Gartland A Goldblatt D Gilbert PB Siber GR Dull P Plotkin SA Evidence for antibody as a protective correlate for COVID-19 vaccines Vaccine 2021 39 4423 4428 34210573 10.1016/j.vaccine.2021.05.063 PMC8142841

65 Slabakova Y Gerenska D Ivanov N Velikova T Immune titers of protection against severe acute respiratory syndrome coronavirus 2: are we there yet? Explor Immunol 2022 2 9 24

66 Monin L Laing AG Muñoz-Ruiz M McKenzie DR Del Molino Del Barrio I Alaguthurai T Domingo-Vila C Hayday TS Graham C Seow J Abdul-Jawad S Kamdar S Harvey-Jones E Graham R Cooper J Khan M Vidler J Kakkassery H Sinha S Davis R Dupont L Francos Quijorna I O'Brien-Gore C Lee PL Eum J Conde Poole M Joseph M Davies D Wu Y Swampillai A North BV Montes A Harries M Rigg A Spicer J Malim MH Fields P Patten P Di Rosa F Papa S Tree T Doores KJ Hayday AC Irshad S Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study Lancet Oncol 2021 22 765 778 33930323 10.1016/S1470-2045(21)00213-8 PMC8078907

67 Fendler A Shepherd STC Au L Wilkinson KA Wu M Byrne F Cerrone M Schmitt AM Joharatnam-Hogan N Shum B Tippu Z Rzeniewicz K Boos LA Harvey R Carlyle E Edmonds K Del Rosario L Sarker S Lingard K Mangwende M Holt L Ahmod H Korteweg J Foley T Bazin J Gordon W Barber T Emslie-Henry A Xie W Gerard CL Deng D Wall EC Agua-Doce A Namjou S Caidan S Gavrielides M MacRae JI Kelly G Peat K Kelly D Murra A Kelly K O'Flaherty M Dowdie L Ash N Gronthoud F Shea RL Gardner G Murray D Kinnaird F Cui W Pascual J Rodney S Mencel J Curtis O Stephenson C Robinson A Oza B Farag S Leslie I Rogiers A Iyengar S Ethell M Messiou C Cunningham D Chau I Starling N Turner N Welsh L van As N Jones RL Droney J Banerjee S Tatham KC O'Brien M Harrington K Bhide S Okines A Reid A Young K Furness AJS Pickering L Swanton C Crick COVID19 consortium, Gandhi S, Gamblin S, Bauer DL, Kassiotis G, Kumar S, Yousaf N, Jhanji S, Nicholson E, Howell M, Walker S, Wilkinson RJ, Larkin J, Turajlic S Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study Nat Cancer 2021 2 1321 1337 10.1038/s43018-021-00274-w PMC7612125 34950880

68 Miteva D Kitanova M Batselova H Lazova S Chervenkov L Peshevska-Sekulovska M Sekulovski M Gulinac M Vasilev GV Tomov L Velikova T The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice Vaccines (Basel) 2023 11 10.3390/vaccines11071181 PMC10385722 37514997

69 Greenberger LM Saltzman LA Senefeld JW Johnson PW DeGennaro LJ Nichols G Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry Blood 2021 138 Suppl 1 185

70 Rüthrich MM Giesen N Mellinghoff SC Rieger CT von Lilienfeld-Toal M Cellular Immune Response after Vaccination in Patients with Cancer-Review on Past and Present Experiences Vaccines (Basel) 2022 10 10.3390/vaccines10020182 PMC8875094 35214642

71 Ehmsen S Asmussen A Jeppesen SS Nilsson AC Østerlev S Vestergaard H Justesen US Johansen IS Frederiksen H Ditzel HJ Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer Cancer Cell 2021 39 1034 1036 34348121 10.1016/j.ccell.2021.07.016 PMC8313483

72 Mairhofer M Kausche L Kaltenbrunner S Ghanem R Stegemann M Klein K Pammer M Rauscher I Salzer HJF Doppler S Habringer A Paar C Kimeswenger S Hoetzenecker W Lamprecht B Lee S Schmitt CA Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer Cancer Cell 2021 39 1171 1172 34450047 10.1016/j.ccell.2021.08.001 PMC8367743

73 Oosting SF van der Veldt AAM GeurtsvanKessel CH Fehrmann RSN van Binnendijk RS Dingemans AC Smit EF Hiltermann TJN den Hartog G Jalving M Westphal TT Bhattacharya A van der Heiden M Rimmelzwaan GF Kvistborg P Blank CU Koopmans MPG Huckriede ALW van Els CACM Rots NY van Baarle D Haanen JBAG de Vries EGE mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial Lancet Oncol 2021 22 1681 1691 34767759 10.1016/S1470-2045(21)00574-X PMC8577843

74 Schmidt AL Labaki C Hsu CY Bakouny Z Balanchivadze N Berg SA Blau S Daher A El Zarif T Friese CR Griffiths EA Hawley JE Hayes-Lattin B Karivedu V Latif T Mavromatis BH McKay RR Nagaraj G Nguyen RH Panagiotou OA Portuguese AJ Puc M Santos Dutra M Schroeder BA Thakkar A Wulff-Burchfield EM Mishra S Farmakiotis D Shyr Y Warner JL Choueiri TK COVID-19 and Cancer Consortium COVID-19 vaccination and breakthrough infections in patients with cancer Ann Oncol 2022 33 340 346 34958894 10.1016/j.annonc.2021.12.006 PMC8704021

75 Goshen-Lago T Waldhorn I Holland R Szwarcwort-Cohen M Reiner-Benaim A Shachor-Meyouhas Y Hussein K Fahoum L Baruch M Peer A Reiter Y Almog R Halberthal M Ben-Aharon I Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer JAMA Oncol 2021 7 1507 1513 34236381 10.1001/jamaoncol.2021.2675 PMC8267843

76 Waldhorn I Holland R Goshen-Lago T Shirman Y Szwarcwort-Cohen M Reiner-Benaim A Shachor-Meyouhas Y Hussein K Fahoum L Peer A Almog R Shaked Y Halberthal M Ben-Aharon I Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors Cancer Discov 2021 11 2430 2435 34475136 10.1158/2159-8290.CD-21-1072

77 Barrière J Chamorey E Adjtoutah Z Castelnau O Mahamat A Marco S Petit E Leysalle A Raimondi V Carles M Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors Ann Oncol 2021 32 1053 1055 33932508 10.1016/j.annonc.2021.04.019 PMC8080507

78 Shroff RT Chalasani P Wei R Pennington D Quirk G Schoenle MV Peyton KL Uhrlaub JL Ripperger TJ Jergović M Dalgai S Wolf A Whitmer R Hammad H Carrier A Scott AJ Nikolich-Žugich J Worobey M Sprissler R Dake M LaFleur BJ Bhattacharya D Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors Nat Med 2021 27 2002 2011 34594036 10.1038/s41591-021-01542-z PMC9004706

79 Wagner A Garner-Spitzer E Schötta AM Orola M Wessely A Zwazl I Ohradanova-Repic A Weseslindtner L Tajti G Gebetsberger L Kratzer B Tomosel E Kutschera M Tobudic S Pickl WF Kundi M Stockinger H Novacek G Reinisch W Zielinski C Wiedermann U SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients-A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease Front Immunol 2022 13 889138 35634285 10.3389/fimmu.2022.889138 PMC9133631

80 Reimann P Ulmer H Mutschlechner B Benda M Severgnini L Volgger A Lang T Atzl M Huynh M Gasser K Grabher C Mink S Fraunberger P Petrausch U Hartmann B Winder T Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response Br J Haematol 2022 196 577 584 34872162 10.1111/bjh.17982

81 Thomas SJ Perez JL Lockhart SP Hariharan S Kitchin N Bailey R Liau K Lagkadinou E Türeci Ö Şahin U Xu X Koury K Dychter SS Lu C Gentile TC Gruber WC Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial Vaccine 2022 40 1483 1492 35131133 10.1016/j.vaccine.2021.12.046 PMC8702495

82 Lee LYW Starkey T Ionescu MC Little M Tilby M Tripathy AR Mckenzie HS Al-Hajji Y Barnard M Benny L Burnett A Cattell EL Charman J Clark JJ Khan S Ghafoor Q Illsley G Harper-Wynne C Hattersley RJ Lee AJX Leonard PC Liu JKH NCRI Consumer Forum, Pang M, Pascoe JS, Platt JR, Potter VA, Randle A, Rigg AS, Robinson TM, Roques TW, Roux RL, Rozmanowski S, Tuthill MH, Watts I, Williams S, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fittall MW, Fowler T, Johnson P Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study Lancet Oncol 2022 23 748 757 35617989 10.1016/S1470-2045(22)00202-9 PMC9126559

83 Thakkar A Pradhan K Duva B Carreno JM Sahu S Thiruthuvanathan V Campbell S Gallego S Bhagat TD Rivera J Choudhary G Olea R Sabalza M Shapiro LC Lee M Quinn R Mantzaris I Chu E Will B Pirofski LA Krammer F Verma A Halmos B Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial Elife 2023 12 10.7554/eLife.83694 PMC10129324 36975207

84 Polack FP Thomas SJ Kitchin N Absalon J Gurtman A Lockhart S Perez JL Pérez Marc G Moreira ED Zerbini C Bailey R Swanson KA Roychoudhury S Koury K Li P Kalina WV Cooper D Frenck RW Jr Hammitt LL Türeci Ö Nell H Schaefer A Ünal S Tresnan DB Mather S Dormitzer PR Şahin U Jansen KU Gruber WC C4591001 Clinical Trial Group Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine N Engl J Med 2020 383 2603 2615 33301246 10.1056/NEJMoa2034577 PMC7745181

85 Haynes L Aging of the Immune System: Research Challenges to Enhance the Health Span of Older Adults Front Aging 2020 1 602108 35822168 10.3389/fragi.2020.602108 PMC9261332

86 Zangemeister-Wittke U Simon HU Myelosuppression. In: Schwab M. Encyclopedia of Cancer. Berlin, Heidelberg: Springer, 2011: 2437-2440

87 Ba Y Shi Y Jiang W Feng J Cheng Y Xiao L Zhang Q Qiu W Xu B Xu R Shen B Luo Z Xie X Chang J Wang M Li Y Shuang Y Niu Z Liu B Zhang J Zhang L Yao H Xie C Huang H Liao W Chen G Zhang X An H Deng Y Gong P Xiong J Yao Q An X Chen C Wang J Wang X Wang Z Xing P Yang S Zhou C Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association Cancer Biol Med 2020 17 896 909 33299642 10.20892/j.issn.2095-3941.2020.0069 PMC7721096

88 Weinblatt ME Coblyn JS Fox DA Fraser PA Holdsworth DE Glass DN Trentham DE Efficacy of low-dose methotrexate in rheumatoid arthritis N Engl J Med 1985 312 818 822 3883172 10.1056/NEJM198503283121303

89 Alqarni AM Zeidler MP How does methotrexate work? Biochem Soc Trans 2020 48 559 567 32239204 10.1042/BST20190803

90 Koźmiński P Halik PK Chesori R Gniazdowska E Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers Int J Mol Sci 2020 21 10.3390/ijms21103483 PMC7279024 32423175

91 Kapetanovic MC Roseman C Jönsson G Truedsson L Saxne T Geborek P Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors Arthritis Rheum 2011 63 3723 3732 21834061 10.1002/art.30580

92 Kapetanovic MC Saxne T Sjöholm A Truedsson L Jönsson G Geborek P Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis Rheumatology (Oxford) 2006 45 106 111 16287919 10.1093/rheumatology/kei193

93 Nived P Pettersson Å Jönsson G Bengtsson AA Settergren B Skattum L Johansson Å Kapetanovic MC Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients Sci Rep 2021 11 9199 33911135 10.1038/s41598-021-88491-2 PMC8080705

94 Ogino MH Tadi P Cyclophosphamide. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-

95 Gauthier SA Weiner HL Cyclophosphamide therapy for MS Int MS J 2005 12 52 58 16417815

96 Elkhalifa A Weiner H Cyclophosphamide Treatment of MS: Current Therapeutic Approaches and Treatment Regimens Int MS J 2010 17 12 18 20663416

97 Ahlmann M Hempel G The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy Cancer Chemother Pharmacol 2016 78 661 671 27646791 10.1007/s00280-016-3152-1

98 Madondo MT Quinn M Plebanski M Low dose cyclophosphamide: Mechanisms of T cell modulation Cancer Treat Rev 2016 42 3 9 26620820 10.1016/j.ctrv.2015.11.005

99 de Lavallade H Khoder A Hart M Sarvaria A Sekine T Alsuliman A Mielke S Bazeos A Stringaris K Ali S Milojkovic D Foroni L Chaidos A Cooper N Gabriel I Apperley J Belsey S Flanagan RJ Goldman J Shpall EJ Kelleher P Marin D Rezvani K Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling Blood 2013 122 227 238 23719297 10.1182/blood-2012-11-465039 PMC5726329